AMRI has completed its previously announced acquisition of Cedarburg Pharmaceuticals Inc., a contract developer and manufacturer of active pharmaceutical ingredients (APIs) for both generic and branded customers.

Total consideration paid was $41 million, including assumption of certain liabilities.

Source: AMRI